Global Plasminogen Deficiency Type 1 Market Analysis and Forecast 2025 – 2035

The Global Plasminogen Deficiency Type 1 Market Size was worth around USD 486.5 Million in 2024 and is predicted to grow to around USD 821.5 Million by 2035 with a compound annual growth rate (CAGR) of 4.88% from 2025 and 2035. The market for plasminogen deficiency type 1 has a number of opportunities to grow due to the increased awareness and approval of specialized treatment regimen.

Market Overview

The Global Industry of Plasminogen Deficiency Type 1 is centered on treating an ultra-rare genetic disorder (hypoplasminogenemia), which is characterized by fibrin accumulation and ligneous lesions, with Ryplazim (plasminogen, human-tvmh) being the first FDA-approved, primary therapy. Type 1 plasminogen deficiency is a rare genetic disorder, affecting individuals developing thick growths, sometimes referred to as woody (ligneous) lesions or pseudomembranes, on the mucous membranes of the body.

Furthermore, targeted enzyme replacement therapy, prophylaxis and personalized dosing, shifting away from surgery, a multidisciplinary approach, and ongoing research focus are some key trends in the PLGD-1 treatment, which greatly improve the quality of life by preventing the recurrence of tissue-damaging pseudomembranes and addressing systemic symptoms.

Innovation and market expansion are anticipated as a result of major players' growing R&D expenditures and the expanding partnerships. For instance, in October 2021, Kedrion announced it had completed the acquisition in North America of the Prometic Life Sciences business.